Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono PharmacareNSE:MONOPHARMA +0.60%11 Receivables Turnover is 1.29 as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 659 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 89.23% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Mono Pharmacare's Revenue for the
six
months ended in Sep. 2025 was ₹663 Mil. Mono Pharmacare's average Accounts Receivable for the
six
months ended in Sep. 2025 was ₹514 Mil.
Hence, Mono Pharmacare's Receivables Turnover for the
six
months ended in Sep. 2025 was 1.29.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Mono Pharmacare Receivables Turnover Related Terms
Mono Pharmacare Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Receivables Turnover of 1.29 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mono Pharmacare and its competitors. According to the industry distribution chart, Mono Pharmacare ranks #588 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 89.2%.
Is Mono Pharmacare's Receivables Turnover too high?
Mono Pharmacare's current Receivables Turnover is 1.29. The Healthcare Providers & Services industry median Receivables Turnover is 7.96. Mono Pharmacare's value of 1.29 is 83.8% below this industry median. Based on the distribution chart, Mono Pharmacare ranks #588 out of 659 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mono Pharmacare has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Receivables Turnover compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #588 out of 659 companies for Receivables Turnover. This places Mono Pharmacare in the lower half of its industry. The industry median Receivables Turnover is 7.96. Mono Pharmacare's value of 1.29 is 83.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.96, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current Receivables Turnover of 1.29 is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current Receivables Turnover is 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Receivables Turnover of 1.29. The current Receivables Turnover is 1.29 and 83.8% below the Healthcare Providers & Services industry median of 7.96. Mono Pharmacare's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Receivables Turnover is 1.29 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
11GF Score
Get the complete analysis for NSE:MONOPHARMA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
